Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
1.90 M
Value Traded
20.91 M
Short % Float
4.46%
Days to Cover
4.5
-4.59%Week
+5.97%1 Month
+18.39%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.12 B
EPS (TTM)
-2.32
P/E Ratio
-
Ent. Value
1.99 B
Total Shares
192.57 M
Float Shares
162.61 M
Insiders
15.55%
Institutions
17.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
TRLV Catalyst Timeline
Dated clinical, regulatory and corporate events for Trulieve Cannabis Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trulieve Cannabis Corp.
93Total events
2Upcoming
11Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
▲Partnership / LicenseCorporate
Closed perpetual royalty-free license for Alien Labs and Connected branded cannabis products in Florida and Texas
▲Dea SchedulingSafety
Received final DEA registrations following rescheduling of state licensed medical marijuana to Schedule III
▲Stock ListingCorporate
Uplisting to the NYSE and rang The Closing Bell to commemorate NYSE listing
▲Product LaunchPost-Market
Opened two dispensaries in Marco Island, Florida and Dunwoody, Georgia
●Restructuring LayoffsCorporate
Completed corporate domestication to Delaware from British Columbia
▲Dea SchedulingSafety
DEA issues initial federal registrations to Trulieve's state-licensed medical marijuana dispensaries
▲Other Regulator MilestoneEx-US Regulatory
DEA inspections completed in Florida, Pennsylvania, and West Virginia
▲Product LaunchPost-Market
Launch of Modern Flower and Roll One branded vape and inhalable flower products in Georgia
●Other Regulator MilestoneEx-US Regulatory
Trulieve completes redomicile from British Columbia to Delaware
▲Product LaunchPost-Market
New product launches including Modern Flower and Roll One in Georgia
◆Other Regulator MilestoneEx-US Regulatory
Hearing to review classification of marijuana begins
marijuanasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Georgia SB 220 signed into law expanding medical cannabis program
medical cannabissource ↗
▲Other Regulator MilestoneEx-US Regulatory
Filed applications for DEA registration for 206 retail locations following Schedule III rescheduling
medical marijuanasource ↗
▼Equity OfferingCorporate
Closed $60 million private placement of senior secured notes due 2030
▲Quarterly UpdateCorporate
Generated $109 million cash flow from operations in first half of 2026
▲Dea SchedulingSafety
State-licensed medical marijuana rescheduled to Schedule III under the Controlled Substances Act
▲Product LaunchPost-Market
Launch of Modern Flower and Roll One branded vape and inhalable flower products in Georgia
▲Debt Royalty FinancingCorporate
Closed US$140 million private placement of 10.5% Senior Secured Notes due 2030
▼Debt Royalty FinancingCorporate
US$100 million private placement of 10.5% Senior Secured Notes due 2030
▲Product LaunchOnwardPost-Market
Expanded distribution of Onward premium THC beverages in Florida and Illinois
▲Debt Royalty FinancingCorporate
Announced planned redemption of $368M senior secured notes due 2026
▲Debt Royalty FinancingCorporate
Notice of redemption for all US$368M 8.0% senior secured notes due 2026
●Partnership / LicenseCorporate
Entered partnership with Professional Pickleball Association and Major League Pickleball
▲Quarterly UpdateCorporate
Trulieve reports Q2 2024 revenue of $303M, up 2% sequentially and 8% YoY
▲Product LaunchPost-Market
Launched adult use sales in Ohio at three locations (Beavercreek, Columbus, Westerville)
Past FDA Catalysts and PDUFA Decisions
How TRLV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TRLV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rivers Kim A.Director, Officer (Chairman and CEO), 10% Owner | Sell | -136,811 1,476,913 held | $8.76 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRLV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TRLV for Q2 2026. | ||||
Ownership Trends
TRLV Short Interest
Shares sold short, counted twice a month.
4.46%
Short % of Float
of tradable shares sold short
7.3M
Shares Sold Short
+12.8% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRLV ranks across every disease it competes in
Competitive Position is a premium feature
See how TRLV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRLV News
-TRLV
Nov 10, 2026▼ -4.8%today
Trulieve Expands Medical Cannabis Access through Riverside Pharmacy in Gainesville, Georgia
Trulieve Cannabis Corp. has launched a new kiosk at Riverside Pharmacy in Gainesville, Georgia, providing qualified patients with access to its medical cannabis products. The kiosk will be staffed by Trulieve educators to offer product information and support. This initiative aligns with Trulieve's mission to enhance patient access and integrate cannabis into healthcare.
Read more →-TRLV
Nov 5, 2026▼ -6%on this news
Trulieve Reports Third Quarter 2026 Results
Trulieve Cannabis Corp. reported third quarter 2026 results with revenues of $230 million and a gross margin of 64%. The company achieved a positive net income of $1 million and generated significant cash flow from operations. Notably, Trulieve received final DEA registrations for medical marijuana, marking a key regulatory milestone.
Read more →-TRLV
Nov 2, 2026▲ +8%on this newsshared move
Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations
Trulieve Cannabis Corp. received DEA registrations for its medical marijuana dispensaries. The company applied in April after the federal rescheduling of medical marijuana to Schedule III. This registration allows Trulieve to operate under the new federal framework for state-licensed businesses.
Read more →-TRLV
Oct 7, 2026Trulieve Repays $65 Million Mortgage Strengthening Balance Sheet
Trulieve Cannabis Corp. has fully repaid a $65 million mortgage, reducing its debt to about $225 million. CEO Kim Rivers stated that this move strengthens the company's financial position and lowers annual interest expenses. The company plans to fund growth initiatives in Georgia and Texas, pending regulatory approvals.
Read more →-TRLV
Oct 6, 2026Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026
Trulieve Cannabis Corp. will conduct a conference call on November 5, 2026, at 8:30 AM ET to discuss its third quarter 2026 financial results. CEO Kim Rivers and CFO Jan Reese will lead the call, which can be accessed via phone or a live audio webcast. The company is recognized as a top performer in the medical cannabis sector.
Read more →-TRLV
Sep 28, 2026Trulieve Announces Exclusive Master Licensing Agreement with Connected for Florida and Texas
Trulieve Cannabis Corp. announced an exclusive licensing agreement with Connected to produce and sell Alien Labs and Connected cannabis products in Florida and Texas. This deal allows Trulieve to expand its product portfolio and maintain high quality standards. The partnership has been successful since 2022, and they plan to introduce new products pending regulatory approvals.
Read more →-TRLV
Sep 22, 2026▲ +8.4%on this news
Trulieve Cannabis Corp. Added to S&P Total Market and S&P Completion Indices
Trulieve Cannabis Corp. has been added to the S&P Total Market Index and S&P Completion Index, marking a significant milestone for the company. This inclusion is anticipated to improve liquidity and attract institutional investors, further enhancing Trulieve's presence in the U.S. capital markets. The company continues to focus on expanding access to cannabis through its operations across several states.
Read more →-TRLV
Sep 4, 2026Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia
Trulieve Cannabis Corp. is set to open a new medical cannabis dispensary in Dunwoody, Georgia, on September 10, 2026. This location aims to enhance access to medical cannabis for patients in the Metro Atlanta area. The grand opening will feature a ribbon cutting, food trucks, discounts, and merchandise giveaways, showcasing Trulieve's commitment to community engagement.
Read more →-TRLV
Sep 2, 2026Trulieve Announces September 2026 Event Participation
Trulieve Cannabis Corp. has announced its participation in two key investor conferences in September 2026. Christine Hersey, the Chief Corporate Affairs and Strategy Officer, will attend the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference on September 9. Additionally, CEO Kim Rivers will participate in the 5th Annual Roth Healthcare Opportunities Conference on September 29.
Read more →-TRLV
Aug 18, 2026Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE
Trulieve Cannabis Corp. celebrated its historic listing on the NYSE by ringing The Closing Bell. This event marks Trulieve as the first U.S. cannabis company to achieve this milestone, reflecting its leadership in the industry. CEO Kim Rivers emphasized the company's commitment to operational excellence and long-term shareholder value.
Read more →-TRLV
Aug 11, 2026Trulieve Completes Redomicile from British Columbia to Delaware
Trulieve Cannabis Corp. has successfully completed its redomicile from British Columbia to Delaware. This strategic move aims to enhance access to U.S. investors and improve eligibility for broader index inclusion. The redomicile was approved by shareholders and finalized on August 11, 2026, with shares continuing to trade under the ticker TRLV.
Read more →-TRLV
Aug 7, 2026Trulieve Reports Second Quarter 2026 Results
Trulieve Cannabis Corp. reported its second quarter 2026 results, highlighting a revenue of $271 million and a gross margin of 60%. Despite achieving a positive adjusted net income of $20 million, the company faced a substantial net loss of $406 million due to the deconsolidation of Harvest operations. The company is also the first U.S. cannabis firm to be listed on the New York Stock Exchange under the ticker TRLV.
Read more →-TRLV
Aug 5, 2026▼ -5.1%on this news
Trulieve Announces August 2026 Event Participation
Trulieve Cannabis Corp. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. Founder and CEO Kim Rivers will engage in a fireside chat and investor meetings during the event. The company continues to expand its operations across several states, emphasizing its commitment to providing high-quality cannabis products.
Read more →-TRLV
Jul 16, 2026Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida
Trulieve Cannabis Corp. announced the opening of a new medical cannabis dispensary in Marco Island, Florida, set to celebrate its grand opening on July 24. The dispensary will offer a variety of products, including in-house brands and partner brands. Trulieve aims to provide high-quality care and products to patients in the area.
Read more →-TRLV
Jul 10, 2026Trulieve Cannabis Corp. to Hold Second Quarter 2026 Results Conference Call on August 7, 2026
Trulieve Cannabis Corp. will hold a conference call on August 7, 2026, to discuss its second quarter financial results. The call will feature CEO Kim Rivers and CFO Jan Reese, who will review the company's performance. Interested parties can join the call via phone or listen to a live webcast.
Read more →-TRLV
Jul 10, 2026Trulieve Named to TIME's America's Best Companies 2026 List
Trulieve Cannabis Corp. has been named to TIME's America's Best Companies 2026 list, recognizing its strong employee satisfaction, financial performance, and sustainability practices. The company is one of only two cannabis firms to receive this honor, reflecting its commitment to expanding access to cannabis. CEO Kim Rivers emphasized the dedication of their team in achieving this recognition.
Read more →-TRLV
Jul 1, 2026Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale
Trulieve Cannabis Corp. celebrated the launch of Georgia's expanded medical cannabis program with a ceremonial first sale in Marietta. The program now allows for a broader range of products, including flower and vaporization options, and expands qualifying conditions for patients. This initiative is seen as a significant advancement for patient access, especially for veterans. Trulieve plans to distribute products through pharmacies across Georgia.
Read more →-TRLV
Jun 26, 2026Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Trulieve Cannabis Corp. announced that CEO Kim Rivers plans to terminate her automatic securities disposition plan (ASDP) on August 11, 2026. The ASDP was initiated in March 2026 for the orderly sale of 2.5 million shares. The first tranche of share sales has been completed, and the second tranche was set to begin in September 2026. This decision may indicate confidence in the company's future performance.
Read more →-TRLV
Jun 9, 2026Trulieve Announces Share Repurchase Program
Trulieve Cannabis Corp. announced a share repurchase program, allowing up to $50 million or 8,495,038 shares to be repurchased over 12 months. CEO Kim Rivers stated this reflects confidence in the company's long-term value and capital allocation strategy. The program will expire on June 16, 2027, and shares bought will be canceled.
Read more →-TRLV
Jun 5, 2026Trulieve Announces Uplist to NYSE
Trulieve Cannabis Corp. will list its subordinate voting shares on the NYSE under ticker TRLV on June 10, 2026. The company became the first U.S. cannabis firm to join a major exchange. This move follows the federal reclassification of medical marijuana to Schedule III. Trulieve plans to expand its shareholder base and increase liquidity.
Read more →About Trulieve Cannabis Corp.
Headquarters3494 MARTIN HURST ROAD, TALLAHASSEE, FL, 32312
BIOPHARMAWATCH ELITE
Trade the next TRLV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime